{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:35:47Z","timestamp":1793936147872,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Human Genetics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ajhg.2019.10.011","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T10:35:50Z","timestamp":1573122950000},"page":"1112-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease"],"prefix":"10.1016","volume":"105","author":[{"given":"Chris","family":"Kay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana de Andrade","family":"Agostinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Findlay-Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Casal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulika","family":"Sumathipala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vajira H.W.","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cornejo-Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Baine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen L\u00facia Ant\u00e3o","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajhg.2019.10.011_bib1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ajhg.2019.10.011_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ajhg.2019.10.011_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-1-4939-7825-0_23","article-title":"Translating Antisense Technology into a Treatment for Huntington\u2019s Disease","volume":"1780","author":"Lane","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ajhg.2019.10.011_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","article-title":"Personalized gene silencing therapeutics for Huntington disease","volume":"86","author":"Kay","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/nat.2018.0720","article-title":"Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients","volume":"28","author":"van Roon-Mom","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ajhg.2019.10.011_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ajhg.2019.10.011_bib8","doi-asserted-by":"crossref","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2017.12.015","article-title":"Effect of early embryonic deletion of huntingtin from pyramidal neurons on the development and long-term survival of neurons in cerebral cortex and striatum","volume":"111","author":"Dragatsis","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ajhg.2019.10.011_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ajhg.2019.10.011_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2164-8-126","article-title":"CAG-encoded polyglutamine length polymorphism in the human genome","volume":"8","author":"Butland","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ajhg.2019.10.011_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajhg.2012.01.005","article-title":"Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region","volume":"90","author":"Lee","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajmg.b.32289","article-title":"Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington\u2019s disease","volume":"168B","author":"Ramos","year":"2015","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/ejhg.2017.125","article-title":"Haplotype-based stratification of Huntington\u2019s disease","volume":"25","author":"Chao","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib16","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0404.2003.00133.x","article-title":"Molecular analysis of Huntington\u2019s disease and linked polymorphisms in the Indian population","volume":"108","author":"Saleem","year":"2003","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ajhg.2019.10.011_bib18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajmg.b.32618","article-title":"The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population","volume":"177","author":"Kay","year":"2018","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ejhg.2016.169","article-title":"The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America","volume":"25","author":"Kay","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ejhg.2013.2","article-title":"Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes","volume":"21","author":"Baine","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib23","series-title":"Epidemiology (in Huntington\u2019s Disease, 4th ed)","author":"Kay","year":"2014"},{"key":"10.1016\/j.ajhg.2019.10.011_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ajhg.2015.07.017","article-title":"Sequence-Level Analysis of the Major European Huntington Disease Haplotype","volume":"97","author":"Lee","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ejhg.2010.229","article-title":"HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia","volume":"19","author":"Warby","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib26","doi-asserted-by":"crossref","first-page":"e107434","DOI":"10.1371\/journal.pone.0107434","article-title":"Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients","volume":"9","author":"Skotte","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajhg.2019.10.011_bib27","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1371\/journal.pgen.0020140","article-title":"Designing siRNA that distinguish between genes that differ by a single nucleotide","volume":"2","author":"Schwarz","year":"2006","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib28","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2008.05734.x","article-title":"Allele-specific silencing of mutant Huntington\u2019s disease gene","volume":"108","author":"Zhang","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ajhg.2019.10.011_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ajhg.2019.10.011_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ajhg.2019.10.011_bib32","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2019.10.011_bib33","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In\u00a0vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/cb500880f","article-title":"Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides","volume":"10","author":"\u00d8stergaard","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ajhg.2019.10.011_bib35","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington\u2019s Disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2019.10.011_bib36","first-page":"4566","article-title":"Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ajhg.2019.10.011_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtn.2017.02.001","article-title":"Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides","volume":"7","author":"\u00d8stergaard","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ajhg.2019.10.011_bib38","doi-asserted-by":"crossref","first-page":"46740","DOI":"10.1038\/srep46740","article-title":"Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells","volume":"7","author":"Miller","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ajhg.2019.10.011_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 Editing of the Mutant Huntingtin Allele In\u00a0Vitro and In\u00a0Vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.10.011_bib40","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ajhg.2019.10.011_bib41","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1093\/nar\/gkf651","article-title":"Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design","volume":"30","author":"Braasch","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2019.10.011_bib42","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ajhg.2019.10.011_bib43","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1093\/nar\/gkl175","article-title":"Design of LNA probes that improve mismatch discrimination","volume":"34","author":"You","year":"2006","journal-title":"Nucleic Acids Res."}],"container-title":["The American Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929719303994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929719303994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:17:56Z","timestamp":1757575076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002929719303994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0002929719303994"],"URL":"https:\/\/doi.org\/10.1016\/j.ajhg.2019.10.011","relation":{},"ISSN":["0002-9297"],"issn-type":[{"value":"0002-9297","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Human Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajhg.2019.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society of Human Genetics.","name":"copyright","label":"Copyright"}]}}